Acute Graft-Versus-Host Disease

Patients who received allogeneic hematopoietic stem cell transplants between 2013 and 2017 demonstrated substantial improvement in survival outcomes and fewer complications than those who underwent transplantation a decade earlier, according to results of a retrospective study published in Annals of Internal Medicine.

A randomized phase 3 study designed to evaluate itacitinib for patients with treatment-naive acute graft-versus-host disease failed to meet its primary and key secondary endpoints, according to the agent’s manufacturer.

ORLANDO — Allogeneic hematopoietic stem cell transplantation appeared effective and generally safe for patients with relapsed or refractory classical Hodgkin lymphoma who received prior immune checkpoint inhibitor therapy, according to retrospective study results presented at ASH Annual Meeting and Exposition.

ORLANDO — The use of high-dose post-transplant cyclophosphamide reduced the incidence of severe acute and chronic graft-versus-host disease without affecting risk for relapse among patients undergoing allogeneic hematopoietic stem cell transplant with matched related or unrelated donors, according to results of the randomized phase 3 HOVON-96 study presented during the plenary session of ASH Annual Meeting and Exposition.

The FDA granted breakthrough therapy designation to abatacept for prevention of moderate to severe acute graft-versus-host disease among individuals who undergo hematopoietic stem cell transplantation from unrelated donors.

A phase 3 trial designed to evaluate ruxolitinib for steroid-refractory acute graft-versus-host disease met its primary endpoint, the agent’s manufacturer announced in a press release.

The FDA granted fast track designation to T-Guard for treatment of patients who develop steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.